Moreover, the use of combination therapy with EGFR, VEGFR [132], and PDGFR inhibitors together with gemcitabine constitutes promising therapy for pancreatic cancer with strong (80–95%) inhibition of tumor growth and protracted survival in the orthotopic nude mouse model [132,133]. Here, PDGFRB is linked to neoplasm.